• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Suez Canal Veterinary Medical Journal. SCVMJ
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 30 (2025)
Volume Volume 29 (2024)
Volume Volume 28 (2023)
Volume Volume 27 (2022)
Volume Volume 26 (2021)
Issue Issue 2
Issue Issue 1
Volume Volume 25 (2020)
Volume Volume 24 (2019)
Volume Volume 23 (2018)
Volume Volume 22 (2017)
Volume Volume 21 (2016)
Volume Volume 20 (2015)
Volume Volume 19 (2014)
Volume Volume 18 (2013)
Said, A., Yousef, S., Ibrahim, I., Mahmoud, Y., El-Beltagy, M. (2021). Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats. Suez Canal Veterinary Medical Journal. SCVMJ, 26(1), 189-218. doi: 10.21608/scvmj.2021.184983
Ashraf Barakat Said; Saleh Yousef; Ibrahim Ibrahim; Yasmina Mahmoud; Marwa El-Beltagy. "Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats". Suez Canal Veterinary Medical Journal. SCVMJ, 26, 1, 2021, 189-218. doi: 10.21608/scvmj.2021.184983
Said, A., Yousef, S., Ibrahim, I., Mahmoud, Y., El-Beltagy, M. (2021). 'Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats', Suez Canal Veterinary Medical Journal. SCVMJ, 26(1), pp. 189-218. doi: 10.21608/scvmj.2021.184983
Said, A., Yousef, S., Ibrahim, I., Mahmoud, Y., El-Beltagy, M. Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats. Suez Canal Veterinary Medical Journal. SCVMJ, 2021; 26(1): 189-218. doi: 10.21608/scvmj.2021.184983

Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats

Article 14, Volume 26, Issue 1, June 2021, Page 189-218  XML PDF (1.8 MB)
Document Type: Original Article
DOI: 10.21608/scvmj.2021.184983
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Barakat Said email 1; Saleh Yousef2; Ibrahim Ibrahim2; Yasmina Mahmoud2; Marwa El-Beltagy2
1Veterinarian
2Biochemistry department, Faculty of Veterinary Medicine, Suez Canal University
Abstract
Chemotherapeutic agents are associated with many side effects. Consequently, much research is interested in the discovery of natural phytochemical compounds that can be used in the prevention and/or treatment of cancer. Ehrlich ascites carcinoma (EAC) model was used to indicate the effectiveness of some chemotherapy and plant sources against cancer due to its similarity with human tumors. The present study was undertaken to investigate antitumor and antioxidant effects of vitamin B17 beside platinum-based drugs in EAC-bearing female rats. Animals were randomly distributed into seven groups (n=7) as follows: Group A, negative control. Group B, positive control that was injected by EAC cells as a cancer model. Group C, EAC-bearing rats were treated with cisplatin. Group D, rats with EAC and were treated by a single dose of oxaliplatin. Group E, rats with EAC and were treated with vitamin B17 (VB17). Group F, rats with EAC and were treated with cisplatin plus vitamin B17. Group G, EAC-bearing rats that were treated by single-dose oxaliplatin plus VB17. One week after the beginning of treatments, blood samples were collected and tumor markers (AFP, CEA, CA19-9, TPA, and LDH), as well as antioxidants biomarkers (SOD, CAT, GSH, and MDA), were measured. Liver and kidney functions were evaluated. Besides, histopathological examination was performed to evaluate antitumor activity and side effects of used drugs on hepatic and renal tissues. Results showed that administration of VB17 alone or in combination with cisplatin or oxaliplatin led to a decrease of tumor markers together with enhancement of antioxidant indicators compared with EAC-bearing rats. Statistical analysis showed a significant (P<0.05) increase in the activities of ALT, AST, ALP accompanied by an increase in the serum levels of creatinine, BUN, and total bilirubin in cisplatin and oxaliplatin treated groups, thus confirming their toxic effects on hepatocytes and renal cells. These findings were supported by histopathological alterations in these groups. VB17 treated groups showed improvement in the studied parameters. From the current study, it could be concluded that vitamin B17 possesses anticancer and antioxidant activities that justify its traditional use, and its potential hepatoprotective effect and kidney ameliorative role.
Keywords
Ehrlich ascites carcinoma; Vitamin B17; Cisplatin; Oxaloplatin; Tumour markers; Antioxidants
Main Subjects
Biochemistry
Statistics
Article View: 396
PDF Download: 618
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.